Cargando…

Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design

The peptide hormone relaxin (RLX), also available as clinical-grade recombinant protein (serelaxin), holds great promise as a cardiovascular and anti-fibrotic agent but is limited by the pharmacokinetic issues common to all peptide drugs. In this study, by a computational modelling chemistry approac...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Ercole, Annunziata, Nistri, Silvia, Pacini, Lorenzo, Carotenuto, Alfonso, Santoro, Federica, Papini, Anna Maria, Bathgate, Ross A. D., Bani, Daniele, Rovero, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402926/
https://www.ncbi.nlm.nih.gov/pubmed/36034864
http://dx.doi.org/10.3389/fphar.2022.942178
_version_ 1784773252986437632
author D'Ercole, Annunziata
Nistri, Silvia
Pacini, Lorenzo
Carotenuto, Alfonso
Santoro, Federica
Papini, Anna Maria
Bathgate, Ross A. D.
Bani, Daniele
Rovero, Paolo
author_facet D'Ercole, Annunziata
Nistri, Silvia
Pacini, Lorenzo
Carotenuto, Alfonso
Santoro, Federica
Papini, Anna Maria
Bathgate, Ross A. D.
Bani, Daniele
Rovero, Paolo
author_sort D'Ercole, Annunziata
collection PubMed
description The peptide hormone relaxin (RLX), also available as clinical-grade recombinant protein (serelaxin), holds great promise as a cardiovascular and anti-fibrotic agent but is limited by the pharmacokinetic issues common to all peptide drugs. In this study, by a computational modelling chemistry approach, we have synthesized and tested a set of low molecular weight peptides based on the putative receptor-binding domain of the B chain of human H1 RLX isoform, with the objective to obtain RLX analogues with improved pharmacokinetic features. Some of them were stabilized to induce the appropriate 3-D conformation by intra-chain tri-azolic staples, which should theoretically enhance their resistance to digestive enzymes making them suited for oral administration. Despite these favourable premises, none of these H1 peptides, either linear or stapled, revealed a sufficient affinity to the specific RLX receptor RXFP1. Moreover, none of them was endowed with any RLX-like biological effects in RXFP1-expressing THP-1 human monocytic cells and mouse NIH-3T3-derived myofibroblasts in in vitro culture, in terms of significantly relevant cAMP elevation and ERK1/2 phosphorylation, which represent two major signal transduction events downstream RXFP1 activation. This was at variance with authentic serelaxin, which induced a clear-cut, significant activation of both these classical RLX signaling pathways. Albeit negative, the results of this study offer additional information about the structural requirements that new peptide therapeutics shall possess to effectively behave as RXFP1 agonists and RLX analogues.
format Online
Article
Text
id pubmed-9402926
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94029262022-08-26 Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design D'Ercole, Annunziata Nistri, Silvia Pacini, Lorenzo Carotenuto, Alfonso Santoro, Federica Papini, Anna Maria Bathgate, Ross A. D. Bani, Daniele Rovero, Paolo Front Pharmacol Pharmacology The peptide hormone relaxin (RLX), also available as clinical-grade recombinant protein (serelaxin), holds great promise as a cardiovascular and anti-fibrotic agent but is limited by the pharmacokinetic issues common to all peptide drugs. In this study, by a computational modelling chemistry approach, we have synthesized and tested a set of low molecular weight peptides based on the putative receptor-binding domain of the B chain of human H1 RLX isoform, with the objective to obtain RLX analogues with improved pharmacokinetic features. Some of them were stabilized to induce the appropriate 3-D conformation by intra-chain tri-azolic staples, which should theoretically enhance their resistance to digestive enzymes making them suited for oral administration. Despite these favourable premises, none of these H1 peptides, either linear or stapled, revealed a sufficient affinity to the specific RLX receptor RXFP1. Moreover, none of them was endowed with any RLX-like biological effects in RXFP1-expressing THP-1 human monocytic cells and mouse NIH-3T3-derived myofibroblasts in in vitro culture, in terms of significantly relevant cAMP elevation and ERK1/2 phosphorylation, which represent two major signal transduction events downstream RXFP1 activation. This was at variance with authentic serelaxin, which induced a clear-cut, significant activation of both these classical RLX signaling pathways. Albeit negative, the results of this study offer additional information about the structural requirements that new peptide therapeutics shall possess to effectively behave as RXFP1 agonists and RLX analogues. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9402926/ /pubmed/36034864 http://dx.doi.org/10.3389/fphar.2022.942178 Text en Copyright © 2022 D'Ercole, Nistri, Pacini, Carotenuto, Santoro, Papini, Bathgate, Bani and Rovero. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
D'Ercole, Annunziata
Nistri, Silvia
Pacini, Lorenzo
Carotenuto, Alfonso
Santoro, Federica
Papini, Anna Maria
Bathgate, Ross A. D.
Bani, Daniele
Rovero, Paolo
Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design
title Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design
title_full Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design
title_fullStr Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design
title_full_unstemmed Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design
title_short Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design
title_sort synthetic short-chain peptide analogues of h1 relaxin lack affinity for the rxfp1 receptor and relaxin-like bioactivity. clues to a better understanding of relaxin agonist design
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402926/
https://www.ncbi.nlm.nih.gov/pubmed/36034864
http://dx.doi.org/10.3389/fphar.2022.942178
work_keys_str_mv AT dercoleannunziata syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT nistrisilvia syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT pacinilorenzo syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT carotenutoalfonso syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT santorofederica syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT papiniannamaria syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT bathgaterossad syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT banidaniele syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign
AT roveropaolo syntheticshortchainpeptideanaloguesofh1relaxinlackaffinityfortherxfp1receptorandrelaxinlikebioactivitycluestoabetterunderstandingofrelaxinagonistdesign